Grant Life Sciences enters into Memorandum of Understanding (MOU) with U.S. State Dep - 500 Beiträge pro Seite
eröffnet am 19.01.06 14:15:31 von
neuester Beitrag 12.07.06 11:24:31 von
neuester Beitrag 12.07.06 11:24:31 von
Beiträge: 38
ID: 1.033.899
ID: 1.033.899
Aufrufe heute: 0
Gesamt: 5.368
Gesamt: 5.368
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| gestern 20:17 | 3359 | |
| gestern 22:26 | 3120 | |
| 08.05.24, 11:56 | 2640 | |
| gestern 17:59 | 2623 | |
| gestern 11:52 | 2549 | |
| vor 1 Stunde | 2160 | |
| vor 1 Stunde | 1791 | |
| vor 1 Stunde | 1666 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.772,85 | +0,46 | 131 | |||
| 2. | 3. | 0,2170 | +3,33 | 125 | |||
| 3. | Neu! | 8,8800 | +57,45 | 108 | |||
| 4. | 4. | 168,47 | -2,04 | 103 | |||
| 5. | 14. | 5,7540 | -2,18 | 56 | |||
| 6. | 2. | 0,2980 | -3,87 | 50 | |||
| 7. | 5. | 2,5600 | -6,91 | 49 | |||
| 8. | 7. | 6,8000 | +2,38 | 38 |
Feedback
Grant Life Sciences enters into Memorandum of Understanding (MOU) with U.S. State Department`s `Bio-Industry Initiative` (BII)
Thursday , January 19, 2006 08:00 ET
MURRAY, Utah, Jan 19, 2006 (BUSINESS WIRE) -- `BII` designed to foster medical and other biological R&D in the former Soviet Union by converting former biowarfare scientists to productive peacetime activities
Grant Life Sciences Inc. (OTC Bulletin Board: GLIF) announced today the signing of a Memorandum of Understanding (MOU) with Dr. Peter Sveshnikov and Dr. Vsevolod Kiselev of the Russian Republic, for the in-licensing of certain of their technologies that are highly complementary to Grants` antibody-based test for detecting cervical cancer. The Sveshnikov/Kiselev technology comes to Grant from the U.S. State Department through its Bio-Industry Initiative (BII) program. The BII is designed to foster medical and other biological research and development in the former Soviet Union by converting former biowarfare scientists to productive peacetime activities.
Sveshnikov/Kiselev have developed an Enzyme-Linked Immunosorbent Assay (ELISA) to detect specific cancer-causing proteins from the human papillomavirus (HPV) -- the obligate cause of cervical cancer -- in the cervical mucous and cells (which make up liquid-based pap samples). The test utilizes certain monoclonal antibodies against these cancer-causing HPV proteins for detection. Thus far, the test is designed to detect cancer-causing proteins from HPV types 16 and 18 which, collectively, are responsible for most cervical disease. This type-specific antigen test, once fully validated and expanded to include additional types of HPV associated with cervical dysplasia and cancer, would be a very synergistic and complementary test to existing Pap technology. It will provide for very low-cost HPV testing as currently performed in Western countries, without the need for additional cervical specimens beyond what is now taken. In addition, large capital outlays would not be required, since most laboratories can readily do ELISA testing.
Sveshnidov/Kiselev have already tested their technology with 1000 Russian samples to confirm the potential of this technology. Grant will be further validating with more specimens from Russia and via the many cervical specimens obtained in the United States under its Institutional Review Board (IRB) approval in controlled clinical settings.
"Together, when validated, Grant will have two complementary cervical dysplasia or cancer diagnostic tests that will work on blood serum or cervical mucous and cells," said Dr. Hun-Chi Lin, President and Chief Scientist at Grant. "A blood-based test is eminently suitable for the 1.7 billion women worldwide who currently are not tested by Pap smear cytology. This inadequacy results in over 300,000 deaths per year. Meanwhile, a test employing cervical mucous or cells is readily fitting for Western medical venues, and has the potential of reducing costs dramatically when compared against those for current HPV DNA-testing. Furthermore, it could significantly reduce expenditures for follow-up referral procedures that turn out to be overwhelmingly negative, with billions of dollars per year in unnecessary medical expenses saved as a consequence."
About Grant Life Sciences Inc.
Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. Currently there are more than 120 million cervical screening tests administered annually in the U.S. and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious or economic reasons. Further information is available at: www.grantlifesciences.com.
Forward-Looking Safe Harbor Statement
With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company`s operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company`s products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.
SOURCE: Grant Life Sciences Inc.
Grant Life Sciences Inc.
Don Rutherford, 949-521-1232
CFO
Copyright Business Wire 2006
Thursday , January 19, 2006 08:00 ET
MURRAY, Utah, Jan 19, 2006 (BUSINESS WIRE) -- `BII` designed to foster medical and other biological R&D in the former Soviet Union by converting former biowarfare scientists to productive peacetime activities
Grant Life Sciences Inc. (OTC Bulletin Board: GLIF) announced today the signing of a Memorandum of Understanding (MOU) with Dr. Peter Sveshnikov and Dr. Vsevolod Kiselev of the Russian Republic, for the in-licensing of certain of their technologies that are highly complementary to Grants` antibody-based test for detecting cervical cancer. The Sveshnikov/Kiselev technology comes to Grant from the U.S. State Department through its Bio-Industry Initiative (BII) program. The BII is designed to foster medical and other biological research and development in the former Soviet Union by converting former biowarfare scientists to productive peacetime activities.
Sveshnikov/Kiselev have developed an Enzyme-Linked Immunosorbent Assay (ELISA) to detect specific cancer-causing proteins from the human papillomavirus (HPV) -- the obligate cause of cervical cancer -- in the cervical mucous and cells (which make up liquid-based pap samples). The test utilizes certain monoclonal antibodies against these cancer-causing HPV proteins for detection. Thus far, the test is designed to detect cancer-causing proteins from HPV types 16 and 18 which, collectively, are responsible for most cervical disease. This type-specific antigen test, once fully validated and expanded to include additional types of HPV associated with cervical dysplasia and cancer, would be a very synergistic and complementary test to existing Pap technology. It will provide for very low-cost HPV testing as currently performed in Western countries, without the need for additional cervical specimens beyond what is now taken. In addition, large capital outlays would not be required, since most laboratories can readily do ELISA testing.
Sveshnidov/Kiselev have already tested their technology with 1000 Russian samples to confirm the potential of this technology. Grant will be further validating with more specimens from Russia and via the many cervical specimens obtained in the United States under its Institutional Review Board (IRB) approval in controlled clinical settings.
"Together, when validated, Grant will have two complementary cervical dysplasia or cancer diagnostic tests that will work on blood serum or cervical mucous and cells," said Dr. Hun-Chi Lin, President and Chief Scientist at Grant. "A blood-based test is eminently suitable for the 1.7 billion women worldwide who currently are not tested by Pap smear cytology. This inadequacy results in over 300,000 deaths per year. Meanwhile, a test employing cervical mucous or cells is readily fitting for Western medical venues, and has the potential of reducing costs dramatically when compared against those for current HPV DNA-testing. Furthermore, it could significantly reduce expenditures for follow-up referral procedures that turn out to be overwhelmingly negative, with billions of dollars per year in unnecessary medical expenses saved as a consequence."
About Grant Life Sciences Inc.
Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. Currently there are more than 120 million cervical screening tests administered annually in the U.S. and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious or economic reasons. Further information is available at: www.grantlifesciences.com.
Forward-Looking Safe Harbor Statement
With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company`s operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company`s products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.
SOURCE: Grant Life Sciences Inc.
Grant Life Sciences Inc.
Don Rutherford, 949-521-1232
CFO
Copyright Business Wire 2006
GLIF top off the day....
Related Events (times are Eastern) Show times in : CET GMT Eastern Central Mountain Pacific
Company Name Ticker Date/Time Type
Grant Life Sciences GLIF Jan 19, 2006
@ 9:00am Small Cap Investment Conference
http://www.vcall.com/IC/ClientPage.asp?ID=91010
Related Events (times are Eastern) Show times in : CET GMT Eastern Central Mountain Pacific
Company Name Ticker Date/Time Type
Grant Life Sciences GLIF Jan 19, 2006
@ 9:00am Small Cap Investment Conference
http://www.vcall.com/IC/ClientPage.asp?ID=91010
Glif ist auf dem richtigen weg.....
Hi Grant-life Fans
Bitte übersetzten oder was gibt es für News?
Wie sind die Kurs Chancen?
mfg
Danke
Bitte übersetzten oder was gibt es für News?
Wie sind die Kurs Chancen?
mfg
Danke
Trading Spotlight
[posting]19.785.460 von BirgiSennfeld am 19.01.06 15:01:23[/posting]Habs schon in den anderen Thread geschrieben. Da wird heute wahrscheinlich kräftig gezockt!
Denke wird werden gleich mal locker durch die 3ct kommen!
Denke wird werden gleich mal locker durch die 3ct kommen!
auf Level2 delayed steht das bid vorbörslich schon auf 2,8!!
Hat jemand realtime-kurse?
Pcquote.com streikt heute bei mir irgendwie
auf level2 nun schon 5MM im bid auf 2,9 und einer auf 2,92
Pcquote.com streikt heute bei mir irgendwie
auf level2 nun schon 5MM im bid auf 2,9 und einer auf 2,92
Clinical Trials
Clinical trials of blood test for HPV-associated cervical cancer are underway
May 31st, 2005
Grant Life Sciences (GLIF) announced that it has reached agreements with two cervical cancer researchers to conduct clinical trials of its cervical cancer diagnostic.
Mark Dodson, MD, is associate professor and division chief of Gynecologic Oncology at the University of Utah School of Medicine. He also has been with the Huntsman Cancer Institute since its inception. There, Dodson treats patients with gynecologic cancers and performs research on cervical disease.
Andrew P. Soisoon, MD, is a professor in the Department of Obstetrics and Gynecology at the University of Utah School of Medicine, a Huntsman Cancer Institute researcher, and is the new primary...
http://www.alumni.utah.edu/u-news/june05/mention.htm
Distinguished cervical cancer researcher Mark Dodson, M.D., is one of two physicians selected to conduct clinical trials of Grant Life Sciences’ cervical cancer diagnostic. Dodson is associate professor and division chief of Gynecologic Oncology at the University of Utah School of Medicine. He also has been with the Huntsman Cancer Institute since its inception. At the Huntsman Cancer Institute, Dodson treats patients with gynecologic cancers and performs research on cervical disease.
Immer noch Offline.....
Es wird was kommen aber was?Neue Homepage oder gleich
auch News?
http://ceocfomagazine.com/
Papillomaviren:
HPV-Infektion (Humanpathogene Papilloma-Viren)
Dr. med. Britta Bürger, Fachärztin für Frauenheilkunde und Geburtshilfe
Was ist eine HPV-Infektion?
Infektionen mit dem Humanpathogenen Papilloma-Virus gehören zu den häufigsten sexuell übertragbaren Viruserkrankungen. Die Ansteckung kann jedoch auch beim Neugeborenen über den Geburtsweg stattfinden. Als Folgen einer HPV-Infektion treten meist harmlose Hauterscheinungen auf. Es existieren aber verschiedene Virus-Untergruppen, von denen einige in Verdacht stehen, bei der Entstehung von bösartigen Erkrankungen beteiligt zu sein. Bewiesen ist mittlerweile der Zusammenhang mit dem Gebärmutterhalskrebs. Wie es zu einer bösartigen (malignen) Entartung infolge einer HPV-Infektion kommen kann, ist allerdings noch nicht vollständig geklärt.
Zum Erreger: Das Virus gehört zu den doppelsträngigen DNA-Viren. In seinem Inneren befinden sich auch noch andere Eiweißstrukturen. Umgeben ist es von einer Kapsel. Die Erbsubstanz des Virus kann mit den Zell- und Regulationsproteinen in den menschlichen Zellen interagieren. Daher besteht auch die Möglichkeit, dass die Zelle entartet.
Welche Krankheiten können durch HP-Viren verursacht werden?
Im Folgenden werden jene Krankheiten aufgelistet, die derzeit mit dem HP-Virus in Verbindung gebracht werden. Es besteht jedoch die Möglichkeit, dass im Verlauf der Forschung noch weitere Zusammenhänge zwischen solchen Infektionen und anderen Folgekrankheiten festgestellt werden.
Haut: Auf der Haut können HP-Viren zur Warzenbildung führen. Auch hier finden sich Formen, die eine maligne Entartung begünstigen.
Kopf und Halsbereich: Warzenbildungen im Hals-Nasen-Ohren-Bereich können ebenfalls auf eine HP-Infektion zurückzuführen sein. Bestimmte Virus-Untergruppen wurden auch bei tumorösen Veränderungen, beispielsweise an den Stimmlippen, festgestellt.
Genitalien: Bislang wurden mehr als 40 Untergruppen des HP-Virus bei Infektionen im Genitalbereich nachgewiesen. Bei den Folgen sind die harmlosen Warzenstrukturen - zu denen auch die Feigwarzen (Kondylome) zählen - von den ernst zunehmenden Virus-Infektionen zu unterscheiden. Für die Kondylome sind die HP-Gruppen 6, 11 und 42 verantwortlich. Bei den HPV-Infektionen, die zu bösartigen Zellveränderungen führen können, den so genannten "High-Risk-Gruppen", findet man die Virus-Untergruppen 16, 18 und andere. Diese Hautveränderungen sind häufig nicht mit bloßem Auge zu erkennen. Die gefährlichen Virus-Untergruppen sind nachweislich nicht nur an der Entstehung von Gebärmutterhalskrebs beteiligt, sondern man findet sie auch bei Krebserkrankungen des Penis, der Vulva (äußeres weibliche Genitale) oder des Anus.
Feigwarzen (Kondylome): Nach einer Inkubationszeit von drei Wochen bis acht Monaten können Feigwarzen (Condylomata accuminata) auftreten. In 10 bis 30 Prozent der Erkrankungen darf mit einem spontanen Verschwinden der Warzen gerechnet werden. Dabei spielt die Immunsituation des jeweiligen Betroffenen eine wichtige Rolle. Allerdings bleibt das Virus in den Zellen oft verborgen und kann ähnlich einer Herpes-Infektion immer dann reaktiviert werden, wenn sich die Immunlage verschlechtert, zum Beispiel bei AIDS bzw. während der Durchführung von Chemotherapien.
High-Risk-HPV-Infektionen: Ähnlich verläuft die Infektion mit den High-Risk-Viren im Bereich des Gebärmutterhalses. Hier bilden die Viren meist keine erhabenen Warzen, wie sie allgemein bekannt sind, sondern eher flächige Strukturen, die nicht so einfach zu erkennen sind. Diese fallen meist erst unter Lupenbetrachtung oder durch Zellveränderungen auf. Manchmal gelingt der Nachweis auch, indem verdünnte Essigsäurelösung auf eine möglicherweise infizierte Fläche aufgebracht wird. Die Hautveränderungen zeigen sich als weißliche Areale.
Die nachweisbaren Gewebeveränderungen können sich einerseits spontan zurückbilden, so dass keine Zellveränderungen mehr nachweisbar sind, andererseits können sie auch zu einem späteren Zeitpunkt erneut wieder auftreten. Es gibt auch Verläufe, wo die Zellveränderungen stetig fortschreiten, bis sich Krebszellen entwickelt haben. Für eine HPV-Infektion typisch ist der Abstrichbefund PAP IIID. Hochgradige Zellveränderungen bis hin zur Krebszelle zeigen sich bei PAP IV a/b oder PAP V. Führt man einen Erregernachweis durch, findet man in absteigender Häufigkeit folgende Untergruppen: 16 , 31, 18 , 33, 35, 52, 73.
Wie wird eine HPV-Infektion diagnostiziert?
Es ist nicht ganz einfach, eine HPV-Infektion zu diagnostizieren. Zur Verfügung stehen dazu unterschiedliche Methoden, die jeweils gewisse Vor- und Nachteile haben. Generelles Ziel der Testverfahren ist es, das Erbmaterial des Virus nachzuweisen. Dazu werden markierte Gen-Bruchstücke an das Virusmaterial angelagert und so sichtbar gemacht. Diese Bruchstücke sind für eine ganz bestimmte Virusgruppe charakteristisch
Das Testergebnis ist jedoch nur dann positiv, wenn die Infektion dazu geführt hat, dass sich das Virus vermehrt. Deshalb lassen sich latente Infektionen - das Virus sitzt inaktiv in den Zellen - nicht feststellen. Ein "negatives Testergebnis" bedeutet daher nicht unbedingt, dass keine Infektion stattgefunden hat. Zudem ist es mit einem Test nur möglich, bestimmte Untergruppen zu erfassen. Andere Gruppen, für die dieser Test nicht konzipiert ist, fallen daher nicht auf.
Es wird was kommen aber was?Neue Homepage oder gleich
auch News?
http://ceocfomagazine.com/
Papillomaviren:
HPV-Infektion (Humanpathogene Papilloma-Viren)
Dr. med. Britta Bürger, Fachärztin für Frauenheilkunde und Geburtshilfe
Was ist eine HPV-Infektion?
Infektionen mit dem Humanpathogenen Papilloma-Virus gehören zu den häufigsten sexuell übertragbaren Viruserkrankungen. Die Ansteckung kann jedoch auch beim Neugeborenen über den Geburtsweg stattfinden. Als Folgen einer HPV-Infektion treten meist harmlose Hauterscheinungen auf. Es existieren aber verschiedene Virus-Untergruppen, von denen einige in Verdacht stehen, bei der Entstehung von bösartigen Erkrankungen beteiligt zu sein. Bewiesen ist mittlerweile der Zusammenhang mit dem Gebärmutterhalskrebs. Wie es zu einer bösartigen (malignen) Entartung infolge einer HPV-Infektion kommen kann, ist allerdings noch nicht vollständig geklärt.
Zum Erreger: Das Virus gehört zu den doppelsträngigen DNA-Viren. In seinem Inneren befinden sich auch noch andere Eiweißstrukturen. Umgeben ist es von einer Kapsel. Die Erbsubstanz des Virus kann mit den Zell- und Regulationsproteinen in den menschlichen Zellen interagieren. Daher besteht auch die Möglichkeit, dass die Zelle entartet.
Welche Krankheiten können durch HP-Viren verursacht werden?
Im Folgenden werden jene Krankheiten aufgelistet, die derzeit mit dem HP-Virus in Verbindung gebracht werden. Es besteht jedoch die Möglichkeit, dass im Verlauf der Forschung noch weitere Zusammenhänge zwischen solchen Infektionen und anderen Folgekrankheiten festgestellt werden.
Haut: Auf der Haut können HP-Viren zur Warzenbildung führen. Auch hier finden sich Formen, die eine maligne Entartung begünstigen.
Kopf und Halsbereich: Warzenbildungen im Hals-Nasen-Ohren-Bereich können ebenfalls auf eine HP-Infektion zurückzuführen sein. Bestimmte Virus-Untergruppen wurden auch bei tumorösen Veränderungen, beispielsweise an den Stimmlippen, festgestellt.
Genitalien: Bislang wurden mehr als 40 Untergruppen des HP-Virus bei Infektionen im Genitalbereich nachgewiesen. Bei den Folgen sind die harmlosen Warzenstrukturen - zu denen auch die Feigwarzen (Kondylome) zählen - von den ernst zunehmenden Virus-Infektionen zu unterscheiden. Für die Kondylome sind die HP-Gruppen 6, 11 und 42 verantwortlich. Bei den HPV-Infektionen, die zu bösartigen Zellveränderungen führen können, den so genannten "High-Risk-Gruppen", findet man die Virus-Untergruppen 16, 18 und andere. Diese Hautveränderungen sind häufig nicht mit bloßem Auge zu erkennen. Die gefährlichen Virus-Untergruppen sind nachweislich nicht nur an der Entstehung von Gebärmutterhalskrebs beteiligt, sondern man findet sie auch bei Krebserkrankungen des Penis, der Vulva (äußeres weibliche Genitale) oder des Anus.
Feigwarzen (Kondylome): Nach einer Inkubationszeit von drei Wochen bis acht Monaten können Feigwarzen (Condylomata accuminata) auftreten. In 10 bis 30 Prozent der Erkrankungen darf mit einem spontanen Verschwinden der Warzen gerechnet werden. Dabei spielt die Immunsituation des jeweiligen Betroffenen eine wichtige Rolle. Allerdings bleibt das Virus in den Zellen oft verborgen und kann ähnlich einer Herpes-Infektion immer dann reaktiviert werden, wenn sich die Immunlage verschlechtert, zum Beispiel bei AIDS bzw. während der Durchführung von Chemotherapien.
High-Risk-HPV-Infektionen: Ähnlich verläuft die Infektion mit den High-Risk-Viren im Bereich des Gebärmutterhalses. Hier bilden die Viren meist keine erhabenen Warzen, wie sie allgemein bekannt sind, sondern eher flächige Strukturen, die nicht so einfach zu erkennen sind. Diese fallen meist erst unter Lupenbetrachtung oder durch Zellveränderungen auf. Manchmal gelingt der Nachweis auch, indem verdünnte Essigsäurelösung auf eine möglicherweise infizierte Fläche aufgebracht wird. Die Hautveränderungen zeigen sich als weißliche Areale.
Die nachweisbaren Gewebeveränderungen können sich einerseits spontan zurückbilden, so dass keine Zellveränderungen mehr nachweisbar sind, andererseits können sie auch zu einem späteren Zeitpunkt erneut wieder auftreten. Es gibt auch Verläufe, wo die Zellveränderungen stetig fortschreiten, bis sich Krebszellen entwickelt haben. Für eine HPV-Infektion typisch ist der Abstrichbefund PAP IIID. Hochgradige Zellveränderungen bis hin zur Krebszelle zeigen sich bei PAP IV a/b oder PAP V. Führt man einen Erregernachweis durch, findet man in absteigender Häufigkeit folgende Untergruppen: 16 , 31, 18 , 33, 35, 52, 73.
Wie wird eine HPV-Infektion diagnostiziert?
Es ist nicht ganz einfach, eine HPV-Infektion zu diagnostizieren. Zur Verfügung stehen dazu unterschiedliche Methoden, die jeweils gewisse Vor- und Nachteile haben. Generelles Ziel der Testverfahren ist es, das Erbmaterial des Virus nachzuweisen. Dazu werden markierte Gen-Bruchstücke an das Virusmaterial angelagert und so sichtbar gemacht. Diese Bruchstücke sind für eine ganz bestimmte Virusgruppe charakteristisch
Das Testergebnis ist jedoch nur dann positiv, wenn die Infektion dazu geführt hat, dass sich das Virus vermehrt. Deshalb lassen sich latente Infektionen - das Virus sitzt inaktiv in den Zellen - nicht feststellen. Ein "negatives Testergebnis" bedeutet daher nicht unbedingt, dass keine Infektion stattgefunden hat. Zudem ist es mit einem Test nur möglich, bestimmte Untergruppen zu erfassen. Andere Gruppen, für die dieser Test nicht konzipiert ist, fallen daher nicht auf.
BUSINESS SUMMARY
Grant Life Sciences, Inc., a development stage company, engages in the research, development, marketing, and sale of diagnostic kits for detecting disease with emphasis on the detection of cervical disease. The company is developing two cervical cancer tests, Enzyme Linked Immunosorbent Assay Test (ELISA) to be run in a laboratory, and a rapid test to be a point-of-care test that would be administered in the hospital, physician’s office, clinic, or at home or in outdoor settings. Its tests would detect the presence or absence of specific antibodies that are produced, only if cancer-causing HPV is present in the body, and consequent oncogenic or cancer-promoting changes occur. The company also holds worldwide rights to diagnostic devices for HIV-1, HIV-2, and dengue fever, and proprietary colloidal gold reagent, an ingredient used by manufacturers of rapid tests as a detectable label. Grant Life Sciences was organized in 1998 and is based in Murray, Utah.
Grant Life Sciences, Inc., a development stage company, engages in the research, development, marketing, and sale of diagnostic kits for detecting disease with emphasis on the detection of cervical disease. The company is developing two cervical cancer tests, Enzyme Linked Immunosorbent Assay Test (ELISA) to be run in a laboratory, and a rapid test to be a point-of-care test that would be administered in the hospital, physician’s office, clinic, or at home or in outdoor settings. Its tests would detect the presence or absence of specific antibodies that are produced, only if cancer-causing HPV is present in the body, and consequent oncogenic or cancer-promoting changes occur. The company also holds worldwide rights to diagnostic devices for HIV-1, HIV-2, and dengue fever, and proprietary colloidal gold reagent, an ingredient used by manufacturers of rapid tests as a detectable label. Grant Life Sciences was organized in 1998 and is based in Murray, Utah.
Alte News:
Grant Life Sciences Announces Collaboration with Allogen Laboratories
03-04-2005
RALEIGH -- Grant Life Sciences Inc. (OTC Bulletin Board: GLIF) announced an agreement with Allogen Laboratories, a wholly owned subsidiary of the Cleveland Clinic Foundation, wherein Allogen will perform testing and validation studies on Grant`s protein-based HPV/cervical cancer diagnostic technology and kits.
As a part of the agreement, Allogen will screen pre-cancerous and cervical cancer patient samples with Grant`s proprietary test to determine the efficacy of the technology. The test, which consists of synthetic peptides derived from human papillomavirus (HPV) proteins, would be the first diagnostic to directly detect cervical cancer.
Dr. Daniel Cook, Director of Allogen Laboratories, stated, "We are very excited about this opportunity to participate in the validation process of this potentially very significant diagnostic test. It`s a great opportunity to explore the potential of new technologies in order to overcome the limitations of current methodologies."
Stan Yakatan, Chairman and CEO of Grant Life Sciences, stated, "We are fortunate to be working with a high quality group like the Cleveland Clinic, which is a strong validation for the cervical cancer diagnostic under development. The market for cervical cancer testing is enormous, and Allogen Laboratories will aid in the speed and quality of our development plans for our non-invasive, protein-based diagnostic."
The human papillomavirus (HPV) causes virtually all cervical cancer. Through a proprietary protein-based technology, the assay under development by Grant looks at HPV in a fashion that identifies cervical cancer, its precursors or the likelihood of its presence. This immunotest includes antibodies especially associated with HPV-caused neoplasias or cancers that are detected with synthetic, proprietary peptides or amino acid sequences derived from certain proteins in the human papillomavirus.
About Allogen Laboratories
Allogen Laboratories, a wholly owned subsidiary of the Cleveland Clinic Foundation, performs a wide variety of diagnostic development and high complexity diagnostic and transplant testing for many areas within the Cleveland Clinic Foundation.
About Grant Life Sciences Inc.
Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. Currently there are more than 120 million cervical screening tests administered annually in the U.S. and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious or economic reasons. Further information is available at: www.grantlifesciences.com.
Und hier:
http://www.clevelandclinic.org/health/health-info/docs/0900/…
http://www.clevelandclinic.org/health/health-info/docs/0100/…
Grant Life Sciences Announces Collaboration with Allogen Laboratories
03-04-2005
RALEIGH -- Grant Life Sciences Inc. (OTC Bulletin Board: GLIF) announced an agreement with Allogen Laboratories, a wholly owned subsidiary of the Cleveland Clinic Foundation, wherein Allogen will perform testing and validation studies on Grant`s protein-based HPV/cervical cancer diagnostic technology and kits.
As a part of the agreement, Allogen will screen pre-cancerous and cervical cancer patient samples with Grant`s proprietary test to determine the efficacy of the technology. The test, which consists of synthetic peptides derived from human papillomavirus (HPV) proteins, would be the first diagnostic to directly detect cervical cancer.
Dr. Daniel Cook, Director of Allogen Laboratories, stated, "We are very excited about this opportunity to participate in the validation process of this potentially very significant diagnostic test. It`s a great opportunity to explore the potential of new technologies in order to overcome the limitations of current methodologies."
Stan Yakatan, Chairman and CEO of Grant Life Sciences, stated, "We are fortunate to be working with a high quality group like the Cleveland Clinic, which is a strong validation for the cervical cancer diagnostic under development. The market for cervical cancer testing is enormous, and Allogen Laboratories will aid in the speed and quality of our development plans for our non-invasive, protein-based diagnostic."
The human papillomavirus (HPV) causes virtually all cervical cancer. Through a proprietary protein-based technology, the assay under development by Grant looks at HPV in a fashion that identifies cervical cancer, its precursors or the likelihood of its presence. This immunotest includes antibodies especially associated with HPV-caused neoplasias or cancers that are detected with synthetic, proprietary peptides or amino acid sequences derived from certain proteins in the human papillomavirus.
About Allogen Laboratories
Allogen Laboratories, a wholly owned subsidiary of the Cleveland Clinic Foundation, performs a wide variety of diagnostic development and high complexity diagnostic and transplant testing for many areas within the Cleveland Clinic Foundation.
About Grant Life Sciences Inc.
Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. Currently there are more than 120 million cervical screening tests administered annually in the U.S. and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious or economic reasons. Further information is available at: www.grantlifesciences.com.
Und hier:
http://www.clevelandclinic.org/health/health-info/docs/0900/…
http://www.clevelandclinic.org/health/health-info/docs/0100/…
Bin seid gestern mit dabei!
Gruss und steigende Kurse!
Gruss und steigende Kurse!
RAiDAR alerts Learn More About RAiDAR-LT
03/07/2006 (17:03 ET) GLIF: Filed New Form PRE 14A, Preliminary Proxy Statement - Edgar
03/07/2006 (17:03 ET) GLIF: Filed New Form PRE 14A, Preliminary Proxy Statement - Edgar
Mid Day Update for Tuesday 3-7-2006
I will have some big alerts coming soon.
GLIF - Volume alert
http://finance.yahoo.com/q?s=GLIF.OB
Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test.
********
I will have some big alerts coming soon.
GLIF - Volume alert
http://finance.yahoo.com/q?s=GLIF.OB
Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test.
********
Patent 6,743,593 :
The invention provides peptides designed to be highly reactive with antibodies from patients infected with oncogenic HPV. Also disclosed is a method for their use in an immunoassay to detect HPV infection and HPV associated epithelial cell abnormalities, most notably those associated with premalignant and malignant epithelial cell lesions. The peptides and the disclosed method are particularly useful for diagnosing carcinomas of the uterine cervix, or pre-stages thereof, or those at risk of development of carcinoma. The detection can be effected on blood samples, or other bodily fluid or tissue, by ascertaining the presence of IgA or IgG antibodies against HPV 16 and/or 18.
http://www.grantlifesciences.com/index.asp?tag=ippatents
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=H…
Viel Glück
The invention provides peptides designed to be highly reactive with antibodies from patients infected with oncogenic HPV. Also disclosed is a method for their use in an immunoassay to detect HPV infection and HPV associated epithelial cell abnormalities, most notably those associated with premalignant and malignant epithelial cell lesions. The peptides and the disclosed method are particularly useful for diagnosing carcinomas of the uterine cervix, or pre-stages thereof, or those at risk of development of carcinoma. The detection can be effected on blood samples, or other bodily fluid or tissue, by ascertaining the presence of IgA or IgG antibodies against HPV 16 and/or 18.
http://www.grantlifesciences.com/index.asp?tag=ippatents
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=H…
Viel Glück
Grant Life Sciences ('Grant') enters into a Memorandum of Understanding with Diagnostic Technologies Ltd. ('DTL') to develop and commercialize Grant's cervical cancer-diagnostic technology
Wednesday, April 12, 2006 09:35 ET
LOS ANGELES, Apr 12, 2006 (BUSINESS WIRE) -- Grant Life Sciences Inc.
The proposed deal would include upfront payment of $250,000 to Grant, plus ongoing royalties upon commercialization of the resulting product; also, DTL will conduct and fund all development costs, including clinical trials, associated with the commercialization of the products developed from Grant's cervical cancer diagnostic technology
Grant Life Sciences Inc. (OTC Bulletin Board: GLIF) announced today that it has entered into a Memo of Understanding (MOU) with Israel-based Diagnostic Technologies Ltd. (DTL) related to Grant's cervical cancer-diagnostic technology (U.S. Patent No. 6,743,593). Under the MOU, Grant will receive an upfront licensing fee of $250,000. In addition, the MOU calls for DTL to conduct all development at its own cost, including clinical trials, associated with the commercialization of the products developed from Grant's cervical cancer-diagnostic technology. Upon commercialization, DTL will pay Grant an ongoing royalty on sales of the products developed, according to the MOU.
A definitive licensing agreement will be signed following appropriate due diligence and a feasibility test. Upon signing, DTL will immediately assume all of the costs associated with turning Grant's core technology related to cervical-cancer diagnostics into a commercially viable product. The diagnostic product based on Grant's technology will augment and complement DTL's suite of diagnostics aimed at the women's health market. Stan Yakatan, Grant's Chairman, together with DTL's Chairman, were instrumental in structuring this MOU, recognizing the considerable synergy of the relationship between the companies.
"This event, once consummated, will represent a most important milestone in the evolution of our company," said Hun-Chi Lin, Ph.D., Grant's President and Chief Scientist. "To date, we have been hampered in our development of our cervical cancer-technology because of capital constraints. The large costs of development, as well as the considerable expenses associated with being a publicly traded company, have hampered our ability to expedite final development of our core technology. This affiliation with DTL will help us accomplish many of our goals and more readily assure success and hoped-for shareholder value appreciation."
"We are happy with the opportunity to extend our current knowledge in developing diagnostic tools and means in the field of women's health to the field of cervical cancer and to fast-forward development and commercialization of a diagnostic product based on Grant's cervical cancer diagnosis technology," said Hamutal Meiri, Ph.D., Chief Executive Officer of DTL. "We hope that their technology will enable the detection of the presence of antibodies produced only by cancer-causing HPV-types and profile them." According to the National Cancer Institute there are some 100 types of HPV. However, only about 7 to 15 of these appear to cause cervical cancer, with certain HPV-types especially virulent in this regard. Cancer-causing HPV-types express certain unique proteins that help trigger the disease. The parties to the MOU believe that the product developed using Grant's technology can distinguish these cancer-causing proteins from those made by non-cancer-causing HPV-types. DTL therefore expects that using Grant's technology will enable it to determine whether a woman has cervical cancer or pre-cervical cancer conditions.
"Upon consummation of this partnership with DTL, Grant will have the 'luxury' of being able to focus its efforts on boosting revenues from sales in Asia of its rapid AccuDx tests for Malaria and Dengue Fever," added Stan Yakatan, Chairman of Grant. "These products, along with its rapid AccuDx tests for HIV-1 and HIV-2, represent an impressive product portfolio, and Grant will be able to look to drive new-business development for Grant Life Sciences in Asia. In addition, the market for cervical cancer testing is enormous, and DTL intends to carry a focused and controlled development of this innovative non-invasive, protein-based diagnostic test."
According to the American Cancer Society, the human papillomavirus (HPV) causes virtually all cervical cancer. Through its proprietary protein-based technology, the assay under development is intended to look at HPV in a fashion that identifies cervical cancer, its precursors or the likelihood of its presence. This immunotest includes antibodies especially associated with HPV-caused neoplasias or cancers that are detected with synthetic, proprietary peptides or amino acid sequences derived from certain proteins in the human papillomavirus.
About Diagnostic Technologies Ltd. (DTL)
DTL, based in Yokneam Illit, Israel, is a private company that has licensed from Technion a technology for using a highly sensitive immunoassay for the prediction of the risk to preeclampsia based on the quantitative determination of placental protein 13 (PP13) in maternal serum for prediction pregnancy disorders. The current test is aimed for the prediction of the risk for preeclampsia. According to the CDC, preeclampsia affects five to seven percent of all pregnant women and represents a serious challenge for obstetricians and prenatal and diagnostic laboratories. This threatening disorder can result in: loss of life; blindness; motor and mental disorders or premature newborns; pregnancy hypertension; and kidney, liver & cardiovascular malfunctioning. It is estimated that nearly $30 billion is spent today in healthcare costs to treat women with preeclampsia and their newborns. The company's in vitro ELISA-based test utilizes a simple blood test for the early prediction of preeclampsia, and it is now in clinical trials. TEUZA, an Israeli venture fund, is the major investor in the Company. On Jan. 31, 2006, PerkinElmer, Inc. (NYSE: PKI), a world leader in Health Sciences and Photonics, announced that it has secured the exclusive global rights to PP13 for identifying patients at risk for preeclampsia developed by DTL.
About Grant Life Sciences Inc.
Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has shown promise in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. According to the CDC there are currently more than 120 million cervical screening tests administered annually in the U.S. and Europe. In developed nations more than 120 million eligible women, 20 years old and above, still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious or economic reasons. Further information is available at: www.grantlifesciences.com.
Forward-Looking Safe Harbor Statement
With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company's products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.
SOURCE: Grant Life Sciences
Grant Life Sciences
Don Rutherford, 949-521-1232
Copyright Business Wire 2006
Wednesday, April 12, 2006 09:35 ET
LOS ANGELES, Apr 12, 2006 (BUSINESS WIRE) -- Grant Life Sciences Inc.
The proposed deal would include upfront payment of $250,000 to Grant, plus ongoing royalties upon commercialization of the resulting product; also, DTL will conduct and fund all development costs, including clinical trials, associated with the commercialization of the products developed from Grant's cervical cancer diagnostic technology
Grant Life Sciences Inc. (OTC Bulletin Board: GLIF) announced today that it has entered into a Memo of Understanding (MOU) with Israel-based Diagnostic Technologies Ltd. (DTL) related to Grant's cervical cancer-diagnostic technology (U.S. Patent No. 6,743,593). Under the MOU, Grant will receive an upfront licensing fee of $250,000. In addition, the MOU calls for DTL to conduct all development at its own cost, including clinical trials, associated with the commercialization of the products developed from Grant's cervical cancer-diagnostic technology. Upon commercialization, DTL will pay Grant an ongoing royalty on sales of the products developed, according to the MOU.
A definitive licensing agreement will be signed following appropriate due diligence and a feasibility test. Upon signing, DTL will immediately assume all of the costs associated with turning Grant's core technology related to cervical-cancer diagnostics into a commercially viable product. The diagnostic product based on Grant's technology will augment and complement DTL's suite of diagnostics aimed at the women's health market. Stan Yakatan, Grant's Chairman, together with DTL's Chairman, were instrumental in structuring this MOU, recognizing the considerable synergy of the relationship between the companies.
"This event, once consummated, will represent a most important milestone in the evolution of our company," said Hun-Chi Lin, Ph.D., Grant's President and Chief Scientist. "To date, we have been hampered in our development of our cervical cancer-technology because of capital constraints. The large costs of development, as well as the considerable expenses associated with being a publicly traded company, have hampered our ability to expedite final development of our core technology. This affiliation with DTL will help us accomplish many of our goals and more readily assure success and hoped-for shareholder value appreciation."
"We are happy with the opportunity to extend our current knowledge in developing diagnostic tools and means in the field of women's health to the field of cervical cancer and to fast-forward development and commercialization of a diagnostic product based on Grant's cervical cancer diagnosis technology," said Hamutal Meiri, Ph.D., Chief Executive Officer of DTL. "We hope that their technology will enable the detection of the presence of antibodies produced only by cancer-causing HPV-types and profile them." According to the National Cancer Institute there are some 100 types of HPV. However, only about 7 to 15 of these appear to cause cervical cancer, with certain HPV-types especially virulent in this regard. Cancer-causing HPV-types express certain unique proteins that help trigger the disease. The parties to the MOU believe that the product developed using Grant's technology can distinguish these cancer-causing proteins from those made by non-cancer-causing HPV-types. DTL therefore expects that using Grant's technology will enable it to determine whether a woman has cervical cancer or pre-cervical cancer conditions.
"Upon consummation of this partnership with DTL, Grant will have the 'luxury' of being able to focus its efforts on boosting revenues from sales in Asia of its rapid AccuDx tests for Malaria and Dengue Fever," added Stan Yakatan, Chairman of Grant. "These products, along with its rapid AccuDx tests for HIV-1 and HIV-2, represent an impressive product portfolio, and Grant will be able to look to drive new-business development for Grant Life Sciences in Asia. In addition, the market for cervical cancer testing is enormous, and DTL intends to carry a focused and controlled development of this innovative non-invasive, protein-based diagnostic test."
According to the American Cancer Society, the human papillomavirus (HPV) causes virtually all cervical cancer. Through its proprietary protein-based technology, the assay under development is intended to look at HPV in a fashion that identifies cervical cancer, its precursors or the likelihood of its presence. This immunotest includes antibodies especially associated with HPV-caused neoplasias or cancers that are detected with synthetic, proprietary peptides or amino acid sequences derived from certain proteins in the human papillomavirus.
About Diagnostic Technologies Ltd. (DTL)
DTL, based in Yokneam Illit, Israel, is a private company that has licensed from Technion a technology for using a highly sensitive immunoassay for the prediction of the risk to preeclampsia based on the quantitative determination of placental protein 13 (PP13) in maternal serum for prediction pregnancy disorders. The current test is aimed for the prediction of the risk for preeclampsia. According to the CDC, preeclampsia affects five to seven percent of all pregnant women and represents a serious challenge for obstetricians and prenatal and diagnostic laboratories. This threatening disorder can result in: loss of life; blindness; motor and mental disorders or premature newborns; pregnancy hypertension; and kidney, liver & cardiovascular malfunctioning. It is estimated that nearly $30 billion is spent today in healthcare costs to treat women with preeclampsia and their newborns. The company's in vitro ELISA-based test utilizes a simple blood test for the early prediction of preeclampsia, and it is now in clinical trials. TEUZA, an Israeli venture fund, is the major investor in the Company. On Jan. 31, 2006, PerkinElmer, Inc. (NYSE: PKI), a world leader in Health Sciences and Photonics, announced that it has secured the exclusive global rights to PP13 for identifying patients at risk for preeclampsia developed by DTL.
About Grant Life Sciences Inc.
Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has shown promise in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. According to the CDC there are currently more than 120 million cervical screening tests administered annually in the U.S. and Europe. In developed nations more than 120 million eligible women, 20 years old and above, still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious or economic reasons. Further information is available at: www.grantlifesciences.com.
Forward-Looking Safe Harbor Statement
With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company's products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.
SOURCE: Grant Life Sciences
Grant Life Sciences
Don Rutherford, 949-521-1232
Copyright Business Wire 2006
The proposed deal would include upfront payment of $250,000 to Grant, plus ongoing royalties upon commercialization of the resulting product; also, DTL will conduct and fund all development costs, including clinical trials, associated with the commercialization of the products developed from Grant's cervical cancer diagnostic technology ....
Ein Upmove von 20% würde mich heute nicht überraschen.
Kaufdruck kommt auf.
Gruß
Kaufdruck kommt auf.
Gruß
Hi Leute!
Weißt jemand, was mit GLF los ist?
Warum steigt die Aktie so stark? Gab es Nachrichten?
Filinta
Weißt jemand, was mit GLF los ist?
Warum steigt die Aktie so stark? Gab es Nachrichten?
Filinta
Composite Indicator
Trend Spotter TM Buy
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Hold
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Hold
Short Term Indicators Average: 60% - Buy
20-Day Average Volume - 2108535
Medium Term Indicators
40 Day Commodity Channel Index Hold
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Sell
Medium Term Indicators Average: 25% - Buy
50-Day Average Volume - 5952728
Long Term Indicators
60 Day Commodity Channel Index Hold
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 67% - Buy
100-Day Average Volume - 5444038
Overall Average: 56% - Buy
Price Support Pivot Point Resistance
0.0250 0.0220 0.0245 0.0270
es tut sich was
http://www.stockhouse.com/comp_info.asp?symbol=GLIF&table=LI…
schon bei 68 bald is die Aktie Bullish
Trend Spotter TM Buy
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Hold
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Hold
Short Term Indicators Average: 60% - Buy
20-Day Average Volume - 2108535
Medium Term Indicators
40 Day Commodity Channel Index Hold
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Sell
Medium Term Indicators Average: 25% - Buy
50-Day Average Volume - 5952728
Long Term Indicators
60 Day Commodity Channel Index Hold
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 67% - Buy
100-Day Average Volume - 5444038
Overall Average: 56% - Buy
Price Support Pivot Point Resistance
0.0250 0.0220 0.0245 0.0270
es tut sich was
http://www.stockhouse.com/comp_info.asp?symbol=GLIF&table=LI…
schon bei 68
bald is die Aktie Bullish
Grant Life Sciences Chairman Featured in Exclusive Interview With WallSt.net
NEW YORK, July 7 /PRNewswire/ -- On July 5, Stan Yakatan, Chairman of
Grant Life Sciences, Inc. (OTC Bulletin Board: GLIF) updated the investment
community in an exclusive interview with http://www.wallst.net . Topics covered in
the interview include an overview of the Company and the markets it serves,
recent press releases, current capitalization, upcoming strategic and
financial milestones.
To hear the interview in its entirety, visit http://www.wallst.net , and click
on "Interviews." Interviews require free registration, and can be accessed
either by locating the respective company's ticker symbol under the
appropriate exchange on the left-hand column of the "Interviews" section of
the site, or by entering the respective company's ticker symbol in the
Search Archive window.
About Grant Life Sciences, Inc.
Grant Life Sciences, Inc. develops products to improve the efficiency
of detecting and diagnosing cervical cancer, including a sensitive,
reliable, non-invasive, point-of-care test. The diagnostic assay being
developed by the Company has shown promise in detecting cervical cancer and
its precursors, a disease that kills in excess of 300,000 women annually.
According to the CDC there are currently more than 120 million cervical
screening tests administered annually in the U.S. and Europe. In developed
nations more than 120 million eligible women, 20 years old and above, still
do not get Pap smears, and globally more than 1.7 billion over the age of
20 have never been checked due to cultural, religious or economic reasons.
Further information is available at: http://www.grantlifesciences.com .
About WallSt.net
http://www.wallst.net is owned and operated by WallStreet Direct, Inc., a
wholly owned subsidiary of Financial Media Group, Inc. The website is a
leading provider of financial news, media, tools and community-driven
applications for investors. http://www.wallst.net offers visitors free membership
to its in-depth executive interviews, exclusive editorial content, breaking
news, and several proprietary applications. In addition to its website,
WallStreet Direct organizes investor conferences, publishes a newspaper,
and provides multimedia advertising solutions to small and mid-sized
publicly traded companies. We are expecting to receive one hundred seventy
five dollars from Grant Life Sciences, Inc. for the dissemination of this
press release. For a complete list of our advertisers, and advertising
relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp
(Logo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO)
Contact:
Nick Iyer
Digital Wall Street, Inc.
1-800-4-WALL-ST
NEW YORK, July 7 /PRNewswire/ -- On July 5, Stan Yakatan, Chairman of
Grant Life Sciences, Inc. (OTC Bulletin Board: GLIF) updated the investment
community in an exclusive interview with http://www.wallst.net . Topics covered in
the interview include an overview of the Company and the markets it serves,
recent press releases, current capitalization, upcoming strategic and
financial milestones.
To hear the interview in its entirety, visit http://www.wallst.net , and click
on "Interviews." Interviews require free registration, and can be accessed
either by locating the respective company's ticker symbol under the
appropriate exchange on the left-hand column of the "Interviews" section of
the site, or by entering the respective company's ticker symbol in the
Search Archive window.
About Grant Life Sciences, Inc.
Grant Life Sciences, Inc. develops products to improve the efficiency
of detecting and diagnosing cervical cancer, including a sensitive,
reliable, non-invasive, point-of-care test. The diagnostic assay being
developed by the Company has shown promise in detecting cervical cancer and
its precursors, a disease that kills in excess of 300,000 women annually.
According to the CDC there are currently more than 120 million cervical
screening tests administered annually in the U.S. and Europe. In developed
nations more than 120 million eligible women, 20 years old and above, still
do not get Pap smears, and globally more than 1.7 billion over the age of
20 have never been checked due to cultural, religious or economic reasons.
Further information is available at: http://www.grantlifesciences.com .
About WallSt.net
http://www.wallst.net is owned and operated by WallStreet Direct, Inc., a
wholly owned subsidiary of Financial Media Group, Inc. The website is a
leading provider of financial news, media, tools and community-driven
applications for investors. http://www.wallst.net offers visitors free membership
to its in-depth executive interviews, exclusive editorial content, breaking
news, and several proprietary applications. In addition to its website,
WallStreet Direct organizes investor conferences, publishes a newspaper,
and provides multimedia advertising solutions to small and mid-sized
publicly traded companies. We are expecting to receive one hundred seventy
five dollars from Grant Life Sciences, Inc. for the dissemination of this
press release. For a complete list of our advertisers, and advertising
relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp
(Logo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO)
Contact:
Nick Iyer
Digital Wall Street, Inc.
1-800-4-WALL-ST
Seit über 50 Jahren läuft das so ab:
Der Pap-Test ist eine Methode zur Beurteilung von Zellen. Diese werden von Muttermund und Gebärmutterhals abgestrichen und anschließend unter dem Mikroskop untersucht. Der Name des Tests geht auf den Anatomen George Papanicolaou zurück, der die Methode in den USA entwickelte. Als Teil des Krebsfrüherkennungsprogramms wird der Zellabstrich von den gesetzlichen Krankenkassen bezahlt.
Der Pap-Test ist eine Methode zur Beurteilung von Zellen. Diese werden von Muttermund und Gebärmutterhals abgestrichen und anschließend unter dem Mikroskop untersucht. Der Name des Tests geht auf den Anatomen George Papanicolaou zurück, der die Methode in den USA entwickelte. Als Teil des Krebsfrüherkennungsprogramms wird der Zellabstrich von den gesetzlichen Krankenkassen bezahlt.
Auch der Labortest ist nicht immer absolut zuverlässig:
Da in der Praxis häufig mehrere Abstriche für die Erstellung des Befundes durchgeführt werden, liegt die Treffsicherheit des Tests bei ungefähr 90 Prozent. So genannte "falsch negative" Testergebnisse, bei denen vorliegende Veränderungen übersehen werden, lassen sich durch eine korrekte, den Vorschriften entsprechende Entnahme der Zellen und Auswertung des Abstrichs im Labor weitgehend vermeiden, aber nicht ganz verhindern.
Da in der Praxis häufig mehrere Abstriche für die Erstellung des Befundes durchgeführt werden, liegt die Treffsicherheit des Tests bei ungefähr 90 Prozent. So genannte "falsch negative" Testergebnisse, bei denen vorliegende Veränderungen übersehen werden, lassen sich durch eine korrekte, den Vorschriften entsprechende Entnahme der Zellen und Auswertung des Abstrichs im Labor weitgehend vermeiden, aber nicht ganz verhindern.
Der Name des Tests geht auf den Anatomen George Papanicolaou zurück, der die Methode in den USA entwickelte. Als Teil des Krebsfrüherkennungsprogramms wird der Zellabstrich von den gesetzlichen Krankenkassen bezahlt.
Der Test wird seit über 50 Jahren praktiziert.
George Nicolas Papanicolaou (* 13. Mai 1883 in Kymi, Euböa, Griechenland; † 19. Februar 1962), griechisch Γεώργιος Παπανικολάου, war ein griechischer Arzt und Pathologe.
George Nicolas Papanicolaou (* 13. Mai 1883 in Kymi, Euböa, Griechenland; † 19. Februar 1962), griechisch Γεώργιος Παπανικολάου, war ein griechischer Arzt und Pathologe.
Hat der alte Test dann ausgedient??
New Screening Technologies
Newer techniques that employ liquid-based cytology (e.g., ThinPrep) have been developed to improve the sensitivity of screening. As with the Papanicolaou (Pap) test, the optimal studies to determine the sensitivity and specificity of these technologies have not been done. Some less than optimal studies show that sensitivity is modestly higher for detecting any degree of cervical intraepithelial neoplasia, with modestly lower specificity. [1] [2] One careful study, however, showed that conventional Pap testing was slightly more sensitive and specific than liquid-based cytology.
New Screening Technologies
Newer techniques that employ liquid-based cytology (e.g., ThinPrep) have been developed to improve the sensitivity of screening. As with the Papanicolaou (Pap) test, the optimal studies to determine the sensitivity and specificity of these technologies have not been done. Some less than optimal studies show that sensitivity is modestly higher for detecting any degree of cervical intraepithelial neoplasia, with modestly lower specificity. [1] [2] One careful study, however, showed that conventional Pap testing was slightly more sensitive and specific than liquid-based cytology.
Der liquid Test ist neuer, aber immer wieder wird hier noch eine Laboruntersuchung benötigt.
Die Treffsicherheit der konventionellen gynäkologischen Zytologie liegt bei 80%. Falsch negative zytologische Befunde sind überwiegend auf unzulängliches Untersuchungsmaterial zurückzuführen. Der für die Diagnostik relevante Bereich wird beim Abstrich nicht erreicht und/oder die entnommenen Zellen gelangen unzureichend auf den Objektträger. Insbesondere beim Watteträger gehen 80% des Untersuchungsmaterial für die Diagnostik verloren.
Ganz klar, es muss ein neuer Test her. GLIF ist gerade an der Arbeit.
Ganz klar, es muss ein neuer Test her. GLIF ist gerade an der Arbeit.
Die Länder stellen langsam um:
The UK has recently switched to using 100% Liquid Based Technologies
The UK has recently switched to using 100% Liquid Based Technologies
Wenn der alte Test 50 Euro kostet, und der von GLIF 25-30 Dollar kosten soll und zugleich ein hohes Maß an Zuverlässigkeit und zudem noch ein der Entnahme zeitnahes Ergebnis liefert......
Dann wäre das Produkt günstiger, schneller in der Durchführung und einfacher zu handhaben.
Fast schon ein "Krebstest to go".
Dann wäre das Produkt günstiger, schneller in der Durchführung und einfacher zu handhaben.
Fast schon ein "Krebstest to go".
So soll es über 100 verschiedene HPV Viren geben. Es wird vermutet, dass nur 7 bis 15 in direkten zusammenhang mit dem Gebährmutterhalskrebs stehen. So lese ich dass. Das würde die hohe Fehlerquote der bisherigen Test mit erklären, oder?
WM finished.... GLIF GO....
digene is nothing (cannot discern cancer), equipment-cost to high. GLIF will have two tests, one for us-market (called elisa) and one for the rest of world (called the quick strip poc test=> low cost). that about cervical-cancer...
digene is nothing (cannot discern cancer), equipment-cost to high. GLIF will have two tests, one for us-market (called elisa) and one for the rest of world (called the quick strip poc test=> low cost). that about cervical-cancer...
Hier die Abacho Übersetzung von Spanisch in Englisch und Englisch in Deutsch:
Nicht fehlerlos wie bekannt, aber das Übernahmeangebot wird klar definiert. Und auch der Übernahmepreis von 0,10 Dollar wird erwänt.
Ist doch jetzt alles klar mit der Nachricht
Lissabon - Zur Quelle von Banco Espirito Santo (BES) sagte heute, dass Banco Espirito Santo der Übernahme zu Grant Life Sciences, Inc Banco Espirito Santo (BES) starten wird, notifie nächsten Freitag die portugiesische Staatssicherheitsmarktkommission (CNMV), dessen es bereit war, auf die Bedingung zu minimalem Annahmeniveau von 75 % zu verzichten, dem sein öffentliches Angebot für den Erwerb von Anteilen von Grant Life Sciences, Inc unterworfen war, in Betracht ziehend, dass die erhaltene Antwort genügend sein wird, um das durch das Übernahmeangebot verfolgte Geschäftsprojekt zu entwickeln. Banco Espirito Santo (BES) wird zum Übernahmeangebot für Grant Life Sciences, Inc mit der Zahlung des US-Dollars von 0.10 $ für jeden losfahren, dass Antwort auf, um Angebot zu neigen, dieses anfängliche Angebot die Grenze des Preises des US-Dollars von 0.12 $ für jeden Anteil der Gesellschaft erreichen konnte. Über Banco Espirito Santo: Experte einer der stärksten und traditionellsten Spieler auf dem portugiesischen Markt, Banco Espíritos Santo, gegründet 1884, ist Portugals führender franchize, wenn es Sie essen, um Sie Banken zu berauben. Sein Ruf ist jedoch durchquerte Grenzen, die Espírito Süßkartoffel von Santo international anerkannt und respektiert machend. In der vordersten Reihe des Internationalen Geschäfts zu sein, ist bestimmt eines der Ergebnisse, die wir behalten wollen. Unsere weit verbreitete Anwesenheit über den Erdball, in mehr als 50 Städten in 17 Ländern, macht uns die internationalsten von portugiesischen Banken und erlaubt am wichtigsten unseren Kunden - Personen, korporativ, Institutions- usw. - sich auf unsere Fähigkeit völlig zu verlassen, ihren Bankverkehrsvoraussetzungen in verschiedenen Erdkunden zu dienen. Finden Sie heraus wohnt über unsere Internationale Anwesenheit, und wie es auch verfolgt, vom Vorteil zu Ihrer Einrichtung sein. Trotz der Tatsache, dass zur großen Zahl unserer internationalen Einheitspflüge tief verbunden mit der Bestimmung von Dienstleistungen zu portugiesischen Emigrant-Gemeinschaften auswärts BES Gruppentätigkeiten Ass pflügen, änderte Experten seine globale Ausbreitung. Zur Liste der relevantesten internationalen Tätigkeiten hilft Zusammenstellung des breiten Spielraums der globalen BES Anwesenheit: Dienstleistungen zu Emigrant-Gemeinschaften (Kontoöffnung, Sparkonten, Überweisungen
Nicht fehlerlos wie bekannt, aber das Übernahmeangebot wird klar definiert. Und auch der Übernahmepreis von 0,10 Dollar wird erwänt.
Ist doch jetzt alles klar mit der Nachricht
Lissabon - Zur Quelle von Banco Espirito Santo (BES) sagte heute, dass Banco Espirito Santo der Übernahme zu Grant Life Sciences, Inc Banco Espirito Santo (BES) starten wird, notifie nächsten Freitag die portugiesische Staatssicherheitsmarktkommission (CNMV), dessen es bereit war, auf die Bedingung zu minimalem Annahmeniveau von 75 % zu verzichten, dem sein öffentliches Angebot für den Erwerb von Anteilen von Grant Life Sciences, Inc unterworfen war, in Betracht ziehend, dass die erhaltene Antwort genügend sein wird, um das durch das Übernahmeangebot verfolgte Geschäftsprojekt zu entwickeln. Banco Espirito Santo (BES) wird zum Übernahmeangebot für Grant Life Sciences, Inc mit der Zahlung des US-Dollars von 0.10 $ für jeden losfahren, dass Antwort auf, um Angebot zu neigen, dieses anfängliche Angebot die Grenze des Preises des US-Dollars von 0.12 $ für jeden Anteil der Gesellschaft erreichen konnte. Über Banco Espirito Santo: Experte einer der stärksten und traditionellsten Spieler auf dem portugiesischen Markt, Banco Espíritos Santo, gegründet 1884, ist Portugals führender franchize, wenn es Sie essen, um Sie Banken zu berauben. Sein Ruf ist jedoch durchquerte Grenzen, die Espírito Süßkartoffel von Santo international anerkannt und respektiert machend. In der vordersten Reihe des Internationalen Geschäfts zu sein, ist bestimmt eines der Ergebnisse, die wir behalten wollen. Unsere weit verbreitete Anwesenheit über den Erdball, in mehr als 50 Städten in 17 Ländern, macht uns die internationalsten von portugiesischen Banken und erlaubt am wichtigsten unseren Kunden - Personen, korporativ, Institutions- usw. - sich auf unsere Fähigkeit völlig zu verlassen, ihren Bankverkehrsvoraussetzungen in verschiedenen Erdkunden zu dienen. Finden Sie heraus wohnt über unsere Internationale Anwesenheit, und wie es auch verfolgt, vom Vorteil zu Ihrer Einrichtung sein. Trotz der Tatsache, dass zur großen Zahl unserer internationalen Einheitspflüge tief verbunden mit der Bestimmung von Dienstleistungen zu portugiesischen Emigrant-Gemeinschaften auswärts BES Gruppentätigkeiten Ass pflügen, änderte Experten seine globale Ausbreitung. Zur Liste der relevantesten internationalen Tätigkeiten hilft Zusammenstellung des breiten Spielraums der globalen BES Anwesenheit: Dienstleistungen zu Emigrant-Gemeinschaften (Kontoöffnung, Sparkonten, Überweisungen
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 90 | ||
| 68 | ||
| 50 | ||
| 40 | ||
| 36 | ||
| 20 | ||
| 15 | ||
| 12 | ||
| 12 | ||
| 11 |
